578 related articles for article (PubMed ID: 27158886)
1. Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ.
Valentín-Nogueras SM; Brodland DG; Zitelli JA; González-Sepúlveda L; Nazario CM
Dermatol Surg; 2016 Jun; 42(6):733-44. PubMed ID: 27158886
[TBL] [Abstract][Full Text] [Related]
2. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment.
Etzkorn JR; Sobanko JF; Elenitsas R; Newman JG; Goldbach H; Shin TM; Miller CJ
J Am Acad Dermatol; 2015 May; 72(5):840-50. PubMed ID: 25774012
[TBL] [Abstract][Full Text] [Related]
3. Outcomes for Invasive Melanomas Treated With Mohs Micrographic Surgery: A Retrospective Cohort Study.
Degesys CA; Powell HB; Hsia LB; Merritt BG
Dermatol Surg; 2019 Feb; 45(2):223-228. PubMed ID: 30199430
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous head and neck melanoma treated with Mohs micrographic surgery.
Bricca GM; Brodland DG; Ren D; Zitelli JA
J Am Acad Dermatol; 2005 Jan; 52(1):92-100. PubMed ID: 15627086
[TBL] [Abstract][Full Text] [Related]
5. Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining for atypical intraepidermal melanocytic proliferation.
Etzkorn JR; Jew OS; Shin TM; Sobanko JF; Neal DE; Miller CJ
J Am Acad Dermatol; 2018 Dec; 79(6):1109-1116.e1. PubMed ID: 30003986
[TBL] [Abstract][Full Text] [Related]
6. The use of Mohs micrographic surgery (MMS) for melanoma in situ (MIS) of the trunk and proximal extremities.
Stigall LE; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2016 Nov; 75(5):1015-1021. PubMed ID: 27473456
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.
Nosrati A; Berliner JG; Goel S; McGuire J; Morhenn V; de Souza JR; Yeniay Y; Singh R; Lee K; Nakamura M; Wu RR; Griffin A; Grimes B; Linos E; Chren MM; Grekin R; Wei ML
JAMA Dermatol; 2017 May; 153(5):436-441. PubMed ID: 28241261
[TBL] [Abstract][Full Text] [Related]
8. National utilization patterns of Mohs micrographic surgery for invasive melanoma and melanoma in situ.
Viola KV; Rezzadeh KS; Gonsalves L; Patel P; Gross CP; Yoo J; Stamell E; Turner RB
J Am Acad Dermatol; 2015 Jun; 72(6):1060-5. PubMed ID: 25824274
[TBL] [Abstract][Full Text] [Related]
9. Digit-Sparing Mohs Surgery for Melanoma.
Terushkin V; Brodland DG; Sharon DJ; Zitelli JA
Dermatol Surg; 2016 Jan; 42(1):83-93. PubMed ID: 26655701
[TBL] [Abstract][Full Text] [Related]
10. Mohs micrographic surgery for melanoma: A prospective multicenter study.
Ellison PM; Zitelli JA; Brodland DG
J Am Acad Dermatol; 2019 Sep; 81(3):767-774. PubMed ID: 31150700
[TBL] [Abstract][Full Text] [Related]
11. Mohs micrographic surgery for the treatment of primary cutaneous melanoma.
Zitelli JA; Brown C; Hanusa BH
J Am Acad Dermatol; 1997 Aug; 37(2 Pt 1):236-45. PubMed ID: 9270510
[TBL] [Abstract][Full Text] [Related]
12. Mohs micrographic surgery with MART-1 immunostaining has durable low local recurrence rates for in situ and invasive melanomas.
Shin TM; Nugent S; Aizman L; Weiner DM; O'Malley V; Sobanko JF; Etzkorn JR; Chu EY; Elenitsas R; Giordano CN; Higgins Ii HW; Miller CJ
J Am Acad Dermatol; 2021 Jan; 84(1):196-198. PubMed ID: 32339704
[No Abstract] [Full Text] [Related]
13. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique.
Albertini JG; Elston DM; Libow LF; Smith SB; Farley MF
Dermatol Surg; 2002 Aug; 28(8):656-65. PubMed ID: 12174054
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of Mohs micrographic surgery for invasive melanoma of the trunk and proximal portion of the extremities.
Burnett ME; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2021 Mar; 84(3):661-668. PubMed ID: 32763327
[TBL] [Abstract][Full Text] [Related]
15. The Current State of Mohs Surgery for the Treatment of Melanoma: A Nationwide Cross-Sectional Survey of Mohs Surgeons.
Siscos SM; Neill BC; Seger EW; Hooton TA; Hocker TLH
Dermatol Surg; 2020 Oct; 46(10):1267-1271. PubMed ID: 32740213
[TBL] [Abstract][Full Text] [Related]
16. Comparison of MITF and Melan-A Immunohistochemistry During Mohs Surgery for Lentigo Maligna-Type Melanoma In Situ and Lentigo Maligna Melanoma.
Christensen KN; Hochwalt PC; Hocker TL; Roenigk RK; Brewer JD; Baum CL; Otley CC; Arpey CJ
Dermatol Surg; 2016 Feb; 42(2):167-75. PubMed ID: 26771682
[TBL] [Abstract][Full Text] [Related]
17. Surgical margins for melanoma in situ.
Kunishige JH; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2012 Mar; 66(3):438-44. PubMed ID: 22196979
[TBL] [Abstract][Full Text] [Related]
18. Comparison of outcomes for malignant melanoma of the face treated using Mohs micrographic surgery and wide local excision.
Chin-Lenn L; Murynka T; McKinnon JG; Arlette JP
Dermatol Surg; 2013 Nov; 39(11):1637-45. PubMed ID: 24164702
[TBL] [Abstract][Full Text] [Related]
19. Treating melanoma in situ and lentigo maligna with Mohs micrographic surgery in Australia.
Foxton GC; Elliott TG; Litterick KA
Australas J Dermatol; 2019 Feb; 60(1):33-37. PubMed ID: 29932208
[TBL] [Abstract][Full Text] [Related]
20. Invasive Melanoma and Melanoma in Situ Treated With Modified Mohs Micrographic Surgery With En Face Permanent Sectioning: A 10-Year Retrospective Review.
Heath M; Woody M; Leitenberger J; Latour E; Bar A
Dermatol Surg; 2020 Aug; 46(8):1004-1013. PubMed ID: 31714384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
